RecruitingRecruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445 · Revolution Medicines, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
About this study
This is a global, randomized, open-label, Phase 3 study designed to evaluate the efficacy and safety of daraxonrasib monotherapy or daraxonrasib plus gemcitabine and nab-paclitaxel compared with standard gemcitabine and nab-paclitaxel when given as first-line treatment in patients with metastatic pancreatic adenocarcinoma.
Patients will be randomized to one of three arms: daraxonrasib (Arm A), daraxonrasib + gemcitabine and nab-paclitaxel (Arm B), or gemcitabine and nab-paclitaxel (Arm C).
Eligibility criteria
Inclusion Criteria:
* At least 18 years old and has provided informed consent.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Histologically or cytologically confirmed pancreatic adenocarcinoma.
* Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.
* Documented RAS mutation status, either mutant or wild-type.
* Measurable disease per RECIST v1.1.
* Adequate organ function (bone marrow, liver, kidney, coagulation).
* Able to take oral medications.
Exclusion Criteria:
* Prior treatment with systemic anticancer therapy in metastatic or locally advanced setting or prior RAS-targeted therapy in any treatment setting.
* Active or known history of untreated central nervous system metastatic disease.
* Any conditions that may affect the ability to take or absorb study drug.
* Major surgery within 28 days prior to randomization.
* Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Study design
Enrollment target: 900 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-03-09
Estimated completion: 2029-03
Last updated: 2026-11-16
Interventions
Drug: daraxonrasibDrug: gemcitabineDrug: nab-paclitaxel
Primary outcomes
- • Progression free survival (PFS) as assessed by blinded independent central review (BICR) (Up to approximately 2 years)
- • Overall survival (OS) (Up to approximately 2 years)
Sponsor
Revolution Medicines, Inc. · industry
Contacts & investigators
ContactRevolution Medicines Study Director · contact · medinfo@revmed.com · 1-844-2-REVMED
All locations (106)
Mayo Clinic - ScottsdaleActive Not Recruiting
Phoenix, Arizona, United States
Honor Health Research InstituteActive Not Recruiting
Scottsdale, Arizona, United States
University of California Los Angeles Health - Hematology/OncologyActive Not Recruiting
Los Angeles, California, United States
University of California San FranciscoActive Not Recruiting
San Francisco, California, United States
Mayo Clinic Cancer Center- FloridaActive Not Recruiting
Jacksonville, Florida, United States
H Lee Moffitt Cancer Center and Research InstituteActive Not Recruiting
Tampa, Florida, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterActive Not Recruiting
Baltimore, Maryland, United States
Dana-Farber Cancer InstituteActive Not Recruiting
Boston, Massachusetts, United States
Henry Ford Health SystemActive Not Recruiting
Detroit, Michigan, United States
Mayo Clinic Cancer Center- RochesterActive Not Recruiting
Rochester, Minnesota, United States
Comprehensive Cancer Centers of NevadaActive Not Recruiting
Henderson, Nevada, United States
Memorial Sloan Kettering Cancer CenterActive Not Recruiting
New York, New York, United States
Duke University Medical CenterActive Not Recruiting
Durham, North Carolina, United States
University of Cincinnati Cancer CenterActive Not Recruiting
Cincinnati, Ohio, United States
Taylor Cancer Research CenterActive Not Recruiting
Maumee, Ohio, United States
SCRI Oncology PartnersActive Not Recruiting
Nashville, Tennessee, United States
SCRI - Texas Oncology DallasActive Not Recruiting
Dallas, Texas, United States
MD Anderson Cancer CenterActive Not Recruiting
Houston, Texas, United States
Huntsman Cancer InstituteActive Not Recruiting
Salt Lake City, Utah, United States
Virginia Cancer SpecialistsActive Not Recruiting
Fairfax, Virginia, United States
Virginia Mason Medical CenterActive Not Recruiting
Seattle, Washington, United States
St. George HospitalRecruiting
Kogarah, New South Wales, Australia
Prince of Wales HospitalRecruiting
Randwick, New South Wales, Australia
GenesisCare St LeonardsRecruiting
Saint Leonards, New South Wales, Australia
Calvary Mater NewcastleRecruiting
Waratah, New South Wales, Australia
Royal Brisbane and Women's HospitalRecruiting
Herston, Queensland, Australia
Epworth HealthCareRecruiting
East Melbourne, Victoria, Australia
Austin Health, Olivia Newton-John Cancer Research & Wellness CentreRecruiting
Heidelberg, Victoria, Australia
Krankenhaus Barmherzige Schwestern LinzRecruiting
Linz, Austria
Krankenhaus der Barmherzigen Brüder Wien-Klinisch wissenschaftliche StudienRecruiting
Vienna, Austria
Institut Jules BordetRecruiting
Anderlecht, Belgium
ImeldaziekenhuisRecruiting
Bonheiden, Belgium
Universitair Ziekenhuis GentRecruiting
Ghent, Belgium
Universitair Ziekenhuis BrusselRecruiting
Jette, Belgium
UZ Leuven (Univ Ziekenhuis Leuven)Recruiting
Leuven, Belgium
CEPON - Centro de Pesquisa Oncologicas de Santa CatarinaRecruiting
Florianópolis, Santa Catarina, Brazil
CEPHO - Centro de Estudos e Pesquisas de Hematologia e OncologiaRecruiting
São Paulo, Brazil
Centre Hospitalier de l'Université de Montréal (CHUM)Recruiting
Québec, Montreal, Canada
Sunnybrook Research InstituteRecruiting
Toronto, Ontario, Canada
Princess Margaret Cancer CentreRecruiting
Toronto, Ontario, Canada
McGill University - Dept. Oncology Clinical Research ProgramRecruiting
Montreal, Quebec, Canada
Aarhus UniversitetshospitalRecruiting
Aarhus N, Denmark
Charité - Campus Virchow-KlinikumRecruiting
Berlin, Germany
Klinikum der Universitaet Muenchen Campus GrosshadernRecruiting
München, Germany
Universitätsklinikum TübingenRecruiting
Tübingen, Germany
Universitätsklinikum WürzburgRecruiting
Würzburg, Germany
The Chinese University of Hong KongRecruiting
Hong Kong, Sha Tin, Hong Kong
The University of Hong Kong, Department of Clinical OncologyRecruiting
Hong Kong, Hong Kong
Fondazione IRCCS Istituto Nazionale dei TumoriRecruiting
Milan, Italy
Istituto Oncologico Veneto IRCCSRecruiting
Padova, Italy
Azienda Ospedaliero Universitaria PisanaRecruiting
Pisa, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCSRecruiting
Roma, Italy
Azienda Ospedaliera Card. G. PanicoRecruiting
Tricase, Italy
Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)Recruiting
Verona, Italy
National Cancer Center - EastRecruiting
Kashiwa, Chiba, Japan
Cancer Institute Hospital - Japan Foundation for Cancer ResearchRecruiting
Koto-Ku, Tokyo, Japan
Chiba Cancer CenterRecruiting
Chiba, Japan
NHO Kyushu Cancer CenterRecruiting
Fukuoka, Japan
Kyushu University HospitalRecruiting
Fukuoka, Japan
Kanagawa Cancer CanterRecruiting
Kanagawa, Japan
Osaka International Cancer InstituteRecruiting
Osaka, Japan
National Cancer Center - TokyoRecruiting
Tokyo, Japan
Wakayama Medical University HospitalRecruiting
Wakayama, Japan
Yamaguchi University HospitalRecruiting
Yamaguchi, Japan
Onze Lieve Vrouwe GasthuisRecruiting
Amsterdam, Netherlands
Erasmus Medisch CentrumRecruiting
Rotterdam, Netherlands
St. Antonius ZiekenhuisRecruiting
Utrecht, Netherlands
Oslo University HospitalRecruiting
Oslo, Norway
St. Olavs Hospital Hf, Universitetssykehuset i TrondheimRecruiting
Trondheim, Norway
Pratia Onkologia KatowiceRecruiting
Katowice, Poland
Pratia MCM KrakowRecruiting
Krakow, Poland
PRATIA S.A. MTZ Clinical Research Powered by PratiaRecruiting
Warsaw, Poland
National Cancer Centre SingaporeRecruiting
Singapore, Singapore
Curie Oncology Pte LtdRecruiting
Singapore, Singapore
Kyungpook National University Chilgok HospitalRecruiting
Daegu, Republic of Korea, South Korea
Dong-A University HospitalRecruiting
Busan, South Korea
Seoul National University HospitalRecruiting
Seoul, South Korea
Severance Hospital, Yonsei University Health SystemRecruiting
Seoul, South Korea
Asan Medical Center - PPDSRecruiting
Seoul, South Korea
Samsung Medical CenterRecruiting
Seoul, South Korea
Hospital Clinic I Provincial de BarcelonaRecruiting
Barcelona, Spain
ICO l'Hospitalet - Hospital Duran i ReynalsRecruiting
Barcelona, Spain
Hospital General Universitario Gregorio MarañonRecruiting
Madrid, Spain
Hospital Universitario Ramon y CajalRecruiting
Madrid, Spain
Hospital Universitario 12 de OctubreRecruiting
Madrid, Spain
Hospital Universitario La Paz - PPDSRecruiting
Madrid, Spain
Hospital Clínico Universitario de ValenciaRecruiting
Valencia, Spain
Sahlgrenska Univeristy Hospital GoteborgRecruiting
Gothenburg, Sweden
Universitaetsspital BaselRecruiting
Basel, Switzerland
Inselspital, Bern University HospitalRecruiting
Bern, Switzerland
Kaohsiung Medical University - Chung-Ho Memorial HospitalRecruiting
Kaohsiung City, Taiwan
China Medical University HospitalRecruiting
Taichung, Taiwan
National Cheng Kung University HospitalRecruiting
Tainan, Taiwan
National Taiwan University HospitalRecruiting
Taipei, Taiwan
Taipei Veterans General HospitalRecruiting
Taipei, Taiwan
Torbay HospitalRecruiting
Torquay, Devon, United Kingdom
Queen Elizabeth Hospital - BirminghamRecruiting
Birmingham, United Kingdom
NHS Cambridge of Addenbrooke HospitalRecruiting
Cambridge, United Kingdom
The Clatterbridge Cancer CentreRecruiting
Liverpool, United Kingdom
Barts HospitalRecruiting
London, United Kingdom
Royal Free HospitalRecruiting
London, United Kingdom
Guy's HospitalRecruiting
London, United Kingdom
Royal Marsden Hospital - LondonRecruiting
London, United Kingdom
Sarah Cannon Research Institute UKRecruiting
London, United Kingdom
University College London HospitalRecruiting
London, United Kingdom
The Christie NHS Foundation TrustRecruiting
Manchester, United Kingdom